Robbins Farley’s AbCellera Biologics ABCL Stock Holding History

Robbins Farley’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-500	Closed	-$5K	–	118
2022 Q1	$5K	Buy	+500	New	+$4.73K	﹤0.01%	106

Other funds holding ABCL

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

GCAC

Guardian Capital Advisors (Canada) Toronto, Ontario, Canada $1.02B AUM 25.29% 1-Year Est. Return

HMC

Harvard Management Company Boston, Massachusetts $4.26B AUM 5.81% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

FFVM

Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return

Robbins Farley's ABCL Position: Q2 2022 in Review

Robbins Farley sold out of AbCellera Biologics (ABCL) in Q2 2022, closing a stake of 500 shares — an estimated $5K sold.

Robbins Farley first reported a position in ABCL in Q1 2022 and held it in 1 quarter. The position peaked at $5K in Q1 2022. 161 funds tracked by Wall St. Rank hold ABCL as of Q2 2022.

Robbins Farley reported no remaining AbCellera Biologics position as of Q2 2022 after selling out during the quarter.
Robbins Farley sold 500 AbCellera Biologics shares in Q2 2022, an estimated $5K.
Robbins Farley first reported a position in AbCellera Biologics in Q1 2022 and held it in 1 quarter.
Robbins Farley's AbCellera Biologics position peaked at $5K in Q1 2022.
161 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2022.

Based on Robbins Farley's 13F filing for Q2 2022, filed 15 Aug 2022.